Vaccines

Today, the Advisory Committee on Immunization Practices (ACIP) unanimously voted the CDC should approve Pfizer-BioNTech and Moderna booster doses for all adults.

The FDA has authorized the Moderna and Pfizer-BioNTech COVID-19 booster shots for all Americans 18 and older.

AstraZeneca’s PROVENT and TACKLE stage 3 trials show its vaccine AZD7442 significantly reduced the risk of severe or fatal COVID-19, even among high-risk populations.

A new report suggests FDA and CDC deliberations may result in booster doses of the mRNA vaccine becoming available by this weekend.

Previous research suggested vaccine efficacy significantly dips after 6 months, but a new study finds COVID-19 cellular immunity remains strong.

States with policy that permitted adolescents to independently choose to receive HPV vaccination had a significantly higher immunization uptake.

2 doses of the India-developed vaccine BBV152 offer 77.8% protection against symptomatic COVID-19 disease.

The Biden administration is also setting mandates for health care workers in facilities receiving federal aid.

The CDC’s Advisory Committee on Immunization Practices voted to recommend hepatitis B, orthopoxviruses, and Ebola vaccines to certain populations, as well as approving 2022 immunization schedules for children, adolescents, and adults.

The ACIP considered the benefits of the newly emergency-authorized vaccine versus the risks of COVID-19 in children aged 5-11 years old.

The latest National Immunization Survey-Child, for children born in 2017- 2018, reveals different rates of vaccination by demographic and disease.

Booster dose eligibility is broadening as the flu season approaches. An expert emphasizes the need to protect for both COVID-19 and the flu in the coming months.

Unpublished data from the company's ongoing pediatric trial show children aged 6 to <12 years old have an antibody response greater than that of young adults.

The median vaccination rate of white American adults was found to be 1.3 times higher than Black and Hispanic adults.

Data presented to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) showed 2 10 µg doses of the Pfizer-BioNTech vaccine to be 90.7% effective in children older than 5 and younger than 12.

The Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky's, MD, endorsement Thursday evening came after 2 days of deliberation from the CDC’s Advisory Committee on Immunization Practices (ACIP) where the group recommended the Moderna and Janssen COVID-19 vaccine “booster” doses.

The CDC’s Advisory Committee on Immunization Practices (ACIP) updated their pneumococcal vaccination recommendations, adding Merck’s sequential vaccine regimen.

The actions taken by the FDA set differing availability of the 3 emergency-authorized vaccines.

The CDC found 2 doses of Pfizer-BioNTech reduced COVID-19 severe outcomes and hospitalization by 93% in adolescents 12-18 years old.

The decision comes after supporting data from a "mix and match" trial last week, and may align with emergency authorizations for the Moderna and Janssen booster doses.

The VRBPAC committee unanimously voted in favor of the Janssen (Johnson & Johnson) COVID-19 vaccine for use under EUA as a booster dose in individuals 18 years and older at least 2 months after a single dose primary vaccination.

The VRBPAC meeting precedes deliberation from the FDA on amending the company's emergency authorization to include booster doses for adult patients.

While receiving a booster of one’s original COVID-19 shot leads to an immune boost, this was heightened among individuals who received a different booster than their primary vaccine.

The FDA suggested that Johnson & Johnson had not conducted an appropriately thorough test to prove its vaccine requires a six-month booster.

Qatar has the highest mRNA vaccine coverage in the world, but their vaccinated population is experiencing significant waning in vaccine efficacy, leading to breakthrough infections.